ArticleImmunology1995
Characterization of a glycosyl-phosphatidylinositol anchor-deficient subline of Raji cells. An analysis of the functional importance of complement inhibitors on the Raji cell line.
Article in Immunology, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 15 citations in OpenAlex.
- Regulatory Architecture of the RCA Gene Cluster Captures an Intragenic TAD Boundary, CTCF-Mediated Chromatin Looping and a Long-Range Intergenic Enhancer.Frontiers in immunology · 2022Article
- Reduced red blood cell surface level of Factor H as a mechanism underlying paroxysmal nocturnal hemoglobinuria.Leukemia · 2021Article
- Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities.Immunology · 2000Article
- Epitope mapping of 10 monoclonal antibodies against the pig analogue of human membrane cofactor protein (MCP).Immunology · 1999Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Analysis of complement inhibitory proteins present on the surface of Raji cells (obtained from the European Collection of Animal Cell Cultures; originally established from human Burkitt's lymphoma) revealed two populations of cells. These populations differed in their expression of the glycosyl-phosphatidylinositol (GPI)-anchored inhibitors CD59 and decay-accelerating factor (DAF). Two stable clones were established by limiting dilution of the original cell culture. Raji+3 expressed CD59 and DAF whereas Raji-26 expressed neither inhibitor. Both clones expressed membrane cofactor protein (MCP). Analyses of other cell surface proteins (CD19, CD35, CD48 and CD58 (transmembrane form)) revealed similar levels of expression of transmembrane proteins by both clones. However, CD48 was expressed only by Raji+3. As CD48, DAF and CD59 are all GPI-anchored molecules it is likely that a defect in the GPI-anchoring mechanism is responsible for the generation of the second population of cells. The two clones demonstrated markedly different sensitivities to complement. When equally sensitized cells from both clones were treated with normal human serum (12.5%) for 1 hr at 37 degrees, the Raji+3 clone was resistant to complement-mediated lysis, whereas approximately 70% of the Raji-26 cells were lysed. However, by using specific antibody to block the function of membrane-bound complement inhibitors, lysis of Raji+3 was demonstrated. Whilst blocking of one inhibitor only on the cell had little effect on cell killing, blocking of two or more inhibitors significantly increased cell lysis. Our results demonstrated that all three inhibitors expressed by these cells contributed to protection against classical pathway-mediated complement activation. However, whilst a limited protective role was seen for MCP, CD59 and DAF appeared to be of far more importance for protection from complement-mediated lysis via the classical pathway.
Indexed as
Identifiers
7490134PMC1384011W2430426792What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.